Emyria Ltd (AU:EMD)
ASX:EMD
Want to see AU:EMD full AI Analyst Report?
Top Page
Emyria Ltd
(Sydney:EMD)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.04
▼(-31.67% Downside)
Action:Reiterated
Date:05/16/26
The score is constrained primarily by weak financial performance (declining revenue, negative margins, and cash flow deficits). Technicals add further pressure with a clear downtrend (price below key moving averages and negative MACD), while valuation is also challenged due to negative earnings (negative P/E) and no dividend support.
Positive Factors
Manageable leverage
A low debt-to-equity ratio (0.12) indicates limited financial leverage, reducing interest burden and preserving borrowing capacity. Over a multi-month horizon this supports operational continuity and strategic flexibility while the company works to stabilise revenues and pursue clinical research.
Negative Factors
Declining revenue
A >20% revenue decline reduces scale economics and weakens the company’s ability to fund clinician networks and trials. If this trend persists over multiple quarters it will constrain reinvestment, limit bargaining power for contracts, and heighten reliance on external financing to maintain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage
A low debt-to-equity ratio (0.12) indicates limited financial leverage, reducing interest burden and preserving borrowing capacity. Over a multi-month horizon this supports operational continuity and strategic flexibility while the company works to stabilise revenues and pursue clinical research.
Read all positive factors
Emyria Ltd (EMD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$32.26M
Dividend YieldN/A
Average Volume (3M)4.06M
Price to Earnings (P/E)―
Beta (1Y)0.88
Revenue Growth22.81%
EPS Growth-110.26%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding806,561,040
10 Day Avg. Volume2,903,931
30 Day Avg. Volume4,056,978
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.37
Price to Sales (P/S)9.01
P/FCF Ratio-4.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$5.90M
Emyria Ltd Business Overview & Revenue Model
Company Description
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuti...
How the Company Makes Money
Emyria’s revenue model is primarily service-based: it generates income by providing fee-for-service mental health care through its clinical operations (e.g., consultations and treatment programs delivered by clinicians) and by conducting research/...
Emyria Ltd Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.18M | 1.39M | 2.20M | 1.59M | 1.82M | 1.98M |
| Gross Profit | -1.23M | 24.48K | -167.55K | -3.32M | -4.41M | -1.58M |
| EBITDA | -3.99M | -2.39M | -13.03M | -6.69M | -8.03M | -4.49M |
| Net Income | -4.55M | -3.14M | -11.46M | -5.13M | -7.33M | -4.91M |
Balance Sheet | ||||||
| Total Assets | 13.66M | 6.62M | 5.43M | 10.16M | 8.25M | 9.06M |
| Cash, Cash Equivalents and Short-Term Investments | 10.50M | 3.57M | 1.57M | 2.73M | 3.88M | 6.53M |
| Total Debt | 1.06M | 613.50K | 1.72M | 1.27M | 632.70K | 949.70K |
| Total Liabilities | 1.56M | 1.31M | 3.00M | 3.37M | 1.93M | 1.88M |
| Stockholders Equity | 12.10M | 5.31M | 2.43M | 6.79M | 6.32M | 7.18M |
Cash Flow | ||||||
| Free Cash Flow | -3.77M | -2.72M | -4.44M | -7.01M | -7.46M | -4.60M |
| Operating Cash Flow | -3.72M | -2.70M | -4.28M | -3.77M | -5.43M | -3.94M |
| Investing Cash Flow | -15.56K | 81.07K | -1.38M | -3.23M | -2.03M | -661.39K |
| Financing Cash Flow | 12.68M | 4.63M | 4.50M | 5.86M | 4.81M | 7.44M |
Emyria Ltd Technical Analysis
Negative
0.06
Price Trends
0.05
Negative
0.05
Negative
0.05
Negative
Market Momentum
>-0.01
Positive
38.17
Neutral
7.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EMD, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and above the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.17 is Neutral, neither overbought nor oversold. The STOCH value of 7.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EMD.
Emyria Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$20.52M | 27.05 | 7.57% | ― | 31.36% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$20.39M | -6.56 | -19.01% | ― | ― | ― | |
43 Neutral | AU$63.35M | -8.33 | -59.96% | ― | ― | ― | |
43 Neutral | AU$24.04M | -3.50 | -1009.84% | ― | 13.69% | 7.57% | |
41 Neutral | AU$32.26M | -6.12 | -52.26% | ― | 22.81% | -110.26% |
* Healthcare Sector Average
AU:EMD
Emyria Ltd
0.04
0.01
42.86%
AU:RHT
Resonance Health Ltd
0.04
<0.01
12.82%
AU:SHG
Singular Health Group Ltd
0.20
-0.20
-50.00%
AU:IME
ImExHS Limited
0.35
0.04
12.90%
AU:PCK
PainChek Ltd
0.12
-0.22
-64.71%
Emyria Ltd Corporate Events
Emyria releases investor video update on evolving psychedelic treatment strategy
Jun 16, 2026
Emyria Limited, a leader in innovative mental health treatments, combines clinical services, real-world data collection and a development pipeline targeting psychedelic-assisted therapies and novel drugs for mental health and neurological diseases...
Emyria Options Lapse, Slightly Streamlining Capital Structure
Jun 8, 2026
Emyria Ltd has notified the market that 200,000 listed options with the code EMDAP, exercisable at $0.384 and expiring on June 7, 2026, have lapsed unexercised. The expiry of these options marginally reduces the company’s potential future sh...
Emyria boosts director equity incentives with major grant of performance rights
May 29, 2026
Emyria Limited has disclosed a change in director Greg Hutchinson’s interests following the issue of 25,580,000 new performance rights under the company’s Employee Incentive Plan. The rights, which were granted for nil consideration an...
Emyria issues 49 million performance rights under employee incentive scheme
May 29, 2026
Emyria Ltd has notified the market of the issue of 49,080,000 unquoted performance rights under its employee incentive scheme. The new securities, which are not intended to be quoted on the ASX, were issued on 28 May 2026 and are designed to align...
Emyria set to fast-track Empax therapist recruitment after TGA widens psychedelic care rules
May 27, 2026
Emyria has welcomed updated recommendations from Australia’s Therapeutic Goods Administration that broaden the range of clinicians eligible to participate in psychedelic-assisted psychotherapy under the Authorised Prescriber scheme. The chan...
Emyria shareholders back capital raisings and director incentives at general meeting
May 1, 2026
Emyria Limited reported that all resolutions put to shareholders at its latest general meeting were passed by poll, reflecting strong investor support for the company’s recent capital management and incentive initiatives. Shareholders ratifi...
Emyria outlines high-risk, early-stage push into psychedelic mental health therapies
Apr 20, 2026
Emyria used its presentation at the Ignite Investment Summit in Singapore to outline its strategy in advanced mental health therapies based on MDMA, psilocybin and related compounds. The company emphasised that these products are still undergoing ...
Emyria moves to digital distribution for upcoming shareholder meeting
Mar 30, 2026
Emyria has called a general meeting of shareholders to be held in Perth on 1 May 2026, with investors able to attend in person or vote via proxy through multiple electronic and physical channels. In line with Australian corporate law and a broader...
Emyria calls extraordinary meeting to ratify major share placement and manager options
Mar 30, 2026
Emyria Limited has called an extraordinary general meeting for 1 May 2026 in West Perth, setting a record date of 29 April 2026 for shareholders eligible to vote. The meeting follows recent capital-raising activity and will allow investors to revi...
Emyria on Track to Launch First Victorian Empax Clinic in Q2 2026
Mar 23, 2026
Emyria says its first Empax clinic in Victoria remains on schedule to begin treating patients in the second quarter of 2026, marking a key step in its national rollout of reimbursable mental health services. The clinic will expand the company̵...
Emyria to Showcase Mental Health Treatment Strategy at NWR Virtual Healthcare Conference
Mar 23, 2026
Emyria Limited, a healthcare innovator focused on mental health and neurological disorders, leverages its Emyria Healthcare clinics and real-world data platform to evaluate emerging therapies, including psychedelic-assisted treatments, and to adva...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.